| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 730.60 | 9.1% | 10.7% |
| Total Income | 755.40 | 8.2% | 10.8% |
| Expenditure | 551.80 | 6.8% | 10.6% |
| PBT | 203.60 | 12.4% | 11.2% |
| Net Profit | 152.20 | 13.6% | 16.4% |
| OPM | 30.67% | 1.96pp | 12.51pp |
| NPM | 20.15% | 0.95pp | 0.97pp |
| EPS | 18.05 | 13.7% | 16.3% |
Dr. Lal PathLabs Reports 10.7% Revenue Growth in Q2 FY26; EBITDA and PAT Increase by 10.8% and 16.4% Respectively
31 Oct 2025 · 31 Oct 2025, 02:37 pm
Summary
Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider, has announced their financial results for the quarter ended September 30, 2025. The company reported a 10.7% increase in revenue in Q2 FY26 and an 11.0% increase in FH26. EBITDA increased by 10.8% with a margin of 30.7%, and PAT increased by 16.4% with a margin of 20.8%. The company also declared an interim dividend of Rs. 7 per share for Q2 FY26 and approved a bonus issue in the ratio of 1:1.
Key Highlights
- 1
10.7% revenue growth in Q2 FY26
- 2
11.0% revenue growth in FH26
- 3
10.8% increase in EBITDA
- 4
30.7% EBITDA margin
- 5
16.4% increase in PAT
- 6
20.8% PAT margin
- 7
Interim dividend of Rs. 7 per share for Q2 FY26
- 8
Bonus issue in the ratio of 1:1
Management Comments
Dr. Lal PathLabs Limited
Please see the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2025.
Informational and educational content only. Not investment advice.